Possible Association of Multicentric Castleman's Disease with Autoimmune Lymphoproliferative Syndrome

Abstract

Multicentric Castleman's disease (MCD) is lymphoproliferative disorder characterized by systemic inflammatory symptoms such as fever and weight loss. Human herpes virus-8 (HHV-8) is thought to be a causable pathogen in all HIV-positive and some HIV-negative MCD patients. Furthermore, the term idiopathic MCD (iMCD) was recently proposed to represent a group of HIV-negative and HHV-8-negative patients with unknown etiologies. Although the international diagnostic criteria for iMCD require exclusion of infection-related disorders, autoimmune/autoinflammatory diseases and malignant/lymphoproliferative disorders to make an iMCD diagnosis, the relationships and differences between these disorders and MCD have not yet been clarified. We recently reported the first case of MCD with autoimmune lymphoproliferative syndrome (ALPS). Although ALPS was included in the iMCD exclusion criteria as an autoimmune/autoinflammatory disease according to the international diagnostic criteria, there is a lack of evidence on the association between MCD and ALPS. In this study, we review the recent understanding of MCD and discuss the possible association between MCD with ALPS.

TAFRO syndrome was effectively treated with an inexpensive novel scheme: A case report

“…For iMCD/TAFRO syndrome treatment, a consensus, evidence‐based treatment guidelines were established in 2018. 9 The monoclonal antibody targeting the interleukin‐6 signaling pathway (siltuximab/tocilizumab) with or without corticosteroids is the preferred first‐line therapy for these patients with a response rate of single anti–IL‐6 mAb 66% (88/144). 10 Rituximab is also a first‐line alternative to anti–IL‐6 mAb therapy for patients who do not have marked cytokine‐driven symptomatology.…”

Retroperitoneal castleman disease mimicking lymph node spread from clear renal cell carcinoma. A case report

“…These are common symptoms that RCC can also manifest, through paraneoplastic syndromes, in about 10–40% of the cases 3 , 4 , . 5 …”

TAFRO syndrome: a case report

“…For iMCD/TAFRO syndrome treatment, a consensus, evidence-based treatment guidelines were established in 2018 9 . The monoclonal antibody targeting the interleukin-6 signaling pathway (siltuximab/tocilizumab) with or without corticosteroids is the preferred first-line therapy for these patients with a response rate of single anti-IL-6 mAb 66% (88/144) 10 .…”